Literature DB >> 15754404

Role of the intracellular receptor domain of gp130 (exon 17) in human inflammatory bowel disease.

Christoph-J Auernhammer1, Kathrin Zitzmann, Fabian Schnitzler, Julia Seiderer, Peter Lohse, George Vlotides, Dieter Engelhardt, Michael Sackmann, Burkhard Goke, Thomas Ochsenkuhn.   

Abstract

AIM: To study the role of the intracellular receptor domain of gp130 in human inflammatory bowel disease (IBD).
METHODS: We amplified and sequenced the complete exon 17 of the human gp130 gene in 146 patients with IBD. According to clinical and histopathological signs, the 146 patients with IBD were classified as having Crohn's disease (n = 73) or ulcerative colitis (n = 63), or as indeterminate status (n = 10).
RESULTS: No mutations in exon 17 of the gp130 gene could be detected in any of the 146 patients with IBD examined.
CONCLUSION: There is no evidence that mutations in exon 17 of the gp130 gene are involved in the pathogenesis of human IBD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15754404      PMCID: PMC4250713          DOI: 10.3748/wjg.v11.i8.1196

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  16 in total

1.  Exon-intron organization of the human gp130 gene.

Authors:  C Szalai; S Toth; A Falus
Journal:  Gene       Date:  2000-02-08       Impact factor: 3.688

Review 2.  The central role of SOCS-3 in integrating the neuro-immunoendocrine interface.

Authors:  C J Auernhammer; S Melmed
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

3.  Inflammation intersection: gp130 balances gut irritation and stomach cancer.

Authors:  Timothy C Wang; James R Goldenring
Journal:  Nat Med       Date:  2002-10       Impact factor: 53.440

4.  Inflammatory bowel disease susceptibility loci defined by genome scan meta-analysis of 1952 affected relative pairs.

Authors:  David A van Heel; Sheila A Fisher; Andrew Kirby; Mark J Daly; John D Rioux; Cathryn M Lewis
Journal:  Hum Mol Genet       Date:  2004-02-19       Impact factor: 6.150

5.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo.

Authors:  R Atreya; J Mudter; S Finotto; J Müllberg; T Jostock; S Wirtz; M Schütz; B Bartsch; M Holtmann; C Becker; D Strand; J Czaja; J F Schlaak; H A Lehr; F Autschbach; G Schürmann; N Nishimoto; K Yoshizaki; H Ito; T Kishimoto; P R Galle; S Rose-John; M F Neurath
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

6.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

Authors:  W R Best; J M Becktel; J W Singleton; F Kern
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

7.  Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease.

Authors:  S Schreiber; P Rosenstiel; J Hampe; S Nikolaus; B Groessner; A Schottelius; T Kühbacher; J Hämling; U R Fölsch; D Seegert
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

8.  Cyclosporine in severe ulcerative colitis refractory to steroid therapy.

Authors:  S Lichtiger; D H Present; A Kornbluth; I Gelernt; J Bauer; G Galler; F Michelassi; S Hanauer
Journal:  N Engl J Med       Date:  1994-06-30       Impact factor: 91.245

Review 9.  Novel neurotrophin-1/B cell-stimulating factor-3 (NNT-1/BSF-3)/cardiotrophin-like cytokine (CLC)--a novel gp130 cytokine with pleiotropic functions.

Authors:  George Vlotides; Kathrin Zitzmann; Gunter K Stalla; Christoph J Auernhammer
Journal:  Cytokine Growth Factor Rev       Date:  2004-10       Impact factor: 7.638

10.  Defective gp130-mediated signal transducer and activator of transcription (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantation.

Authors:  M Ernst; M Inglese; P Waring; I K Campbell; S Bao; F J Clay; W S Alexander; I P Wicks; D M Tarlinton; U Novak; J K Heath; A R Dunn
Journal:  J Exp Med       Date:  2001-07-16       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.